問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taipei Veterans Center Hospital Yuli Branch (在職)

Division of Hematology & Oncology

Division of Psychiatry

China Medical University Hospital (在職)

Division of Hematology & Oncology

Division of General Internal Medicine

Yuli Hospital Ministry of Health and Welfare (在職)

Division of Hematology & Oncology

Division of Psychiatry

National Taiwan University Hospital Yunlin Branch  (在職)

Division of Psychiatry

國立臺灣大學醫學院附設醫院雲林分院

更新時間：2023-09-19

陳姿婷Chen, Tzu-Ting
  • Principal Investigator
  • Clinical Trial Experience (year) 7 years 9 個月

Recruiting Trial

91Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

陳姿婷

China Medical University Hospital

未分科

List

2Cases

2016-08-01 - 2021-01-10

Phase III

A Phase 3, Double-Blind, Placebo-controlled Study of Quizartinib (AC220) Administered in Combination with Induction and Consolidation Chemotherapy, and Administered as Maintenance Therapy in Subjects 18 to 75 Years Old with Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (QuANTUM-First)

  • Condition/Disease

    Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia

  • Test Drug

    Quizartinib (AC220)

Participate Sites
6Sites

Recruiting3Sites

Terminated3Sites

柯博伸
Taipei Veterans General Hospital

2019-11-30 - 2022-05-19

Phase III

A Randomized, Double-Blind, Phase 3 Study to Evaluate the Activity of Momelotinib (MMB) versus Danazol (DAN) in Symptomatic, Anemic Subjects with Primary Myelofibrosis (PMF), Post-Polycythemia Vera (PV) Myelofibrosis, or Post Essential Thrombocythemia (ET) Myelofibrosis who were Previously Treated with JAK Inhibitor Therapy

  • Condition/Disease

    Primary Myelofibrosis (PMF), Post-Polycythemia Vera (PV) Myelofibrosis, or Post Essential Thrombocythemia (ET) Myelofibrosis

  • Test Drug

    Momelotinib Tablets；Danazol Capsules

Participate Sites
4Sites

Not yet recruiting3Sites

Recruiting1Sites

聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB